Stocks With The Most
Fund Call Options
| Name | Net Calls | Calls | Puts |
Return since 30 Jun ‘22 |
|
|---|---|---|---|---|---|
| $77.2M | $115M | $37.5M | 178% |
|
|
| $75.1M | $212M | $137M | 1.12% |
|
|
| $74.6M | $261M | $186M | 66.8% |
|
|
129
Neurocrine Biosciences
NBIX
$13.2B
| $74.3M | $111M | $36.6M | 35.8% |
|
| $74.3M | $278M | $204M | 41.8% |
|
|
| $72.6M | $85.1M | $12.5M | 32.5% |
|
|
| $72M | $113M | $41M | 23.2% |
|
|
| $71.4M | $139M | $67.8M | 181% |
|
|
| $70.5M | $244M | $174M | 23.2% |
|
|
| $70.3M | $75.8M | $5.52M | 5.92% |
|
|
136
Vanguard FTSE Emerging Markets ETF
VWO
$110B
| $69.5M | $95.4M | $26M | 34.5% |
|
| $69.2M | $310M | $241M | 41% |
|
|
| $69.1M | $1.91B | $1.84B | 21.2% |
|
|
| $67.9M | $70.5M | $2.59M | 1.6% |
|
|
| $67.6M | $198M | $131M | 162% |
|
|
| $67.1M | $133M | $65.4M | 139% |
|
|
| $66.4M | $160M | $94M | 41.2% |
|
|
| $66.3M | $294M | $228M | 65.3% |
|
|
| $65.9M | $171M | $105M | 150% |
|
|
| $64.6M | $878M | $813M | 26.2% |
|
|
| $63.7M | $115M | $51.8M | 6.09% |
|
|
| $62.9M | $88.7M | $25.7M | 391% |
|
|
| $62.9M | $72M | $9.06M | 73% |
|
|
| $62.4M | $116M | $53.5M | 1.96% |
|
|
| $60.6M | $134M | $73.6M | 35.8% |
|